Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors

Inventors

Fu, Jiping • Lou, Yan • HE, Yigang

Assignees

Nikang Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11267782-B2

Patent

Publication Date

2022-03-08

Expiration Date


Abstract

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Core Innovation

The invention concerns fluorinated cyclopenta[cd]indene/benzonitrile derivatives, including 3-fluoro-5-oxy substituted benzonitrile connected to a (1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl) motif. The disclosed chemical scope includes variable substituents, stereochemical configurations, pharmaceutically acceptable salts, and deuterium-labeled variants, with deuterium indicated by D, -d3, -1-d, and 2H.

The disclosure further describes fluorinated polycyclic embodiments with substituent variation rules, linker concepts, and ring-forming options within the cyclopenta[cd]indene/benzonitrile framework. It also provides a general Formula (IA)/(I) with extensive substituent definitions and dependent narrowing, including options such as X1 = CH or N, together with defined combinations for R-groups and ring closures.

The patent further relates to tetrahydro-1H-cyclopenta[cd]indene derivatives as small-molecule HIF-2b1 inhibitors and describes inhibition of HIF2b1. It also includes pharmaceutical compositions comprising the disclosed compounds or salts with pharmaceutically acceptable excipients.

Claims Coverage

The independent claims cover four inventive feature groupings: a selected group of specific fluorinated cyclopenta[cd]indene benzonitrile compounds, specific stereochemical configurations, deuterium-labeled variants, and pharmaceutical compositions comprising those compounds with a pharmaceutically acceptable excipient. The compound claims also refer to pharmaceutically acceptable salts.

Defined fluorinated cyclopenta[cd]indene/benzonitrile scaffold

A compound selected from the group consisting of 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile structures, including a pharmaceutically acceptable salt thereof.

Specific stereochemical configuration

A compound defined with stereochemical configuration such as (1S,2aR) and (1R,2aS), as shown by the provided structure.

Deuterium-labeled variants

A compound selected from deuterium-labeled isotopologues such as -1,2,2-d3 and -2,4,6-d3 labeled forms, including deuterated variants and pharmaceutically acceptable salts thereof.

Pharmaceutical composition with pharmaceutically acceptable excipient

A pharmaceutical composition comprising the disclosed fluorinated cyclopenta[cd]indene/benzonitrile compounds, including specified stereochemical and deuterium-labeled variants, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.

The independent claims are directed to identity-defined fluorinated cyclopenta[cd]indene/benzonitrile compounds with specified stereochemistry and optional deuterium labeling, including pharmaceutically acceptable salts, and extend to pharmaceutical compositions containing those compounds together with a pharmaceutically acceptable excipient.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Inhibition of HIF2b1.

Method of treating disease mediated by HIF2b1.

VEGF/HIF-2b1 inhibition assay in 786-O cells with a VEGF ELISA readout and reported EC50 values.

Representative pharmaceutical formulation uses including tablet, capsule, injectable, inhalation, topical gel, ophthalmic solution, and nasal spray.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.